Patent ID: 11931345
Assignee: CIRIUS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 11:
12. A method of treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes mellitus, and/or metabolic syndrome, comprising:
(i) administering to a subject in need thereof a daily dosage of from about 62.5 mg to about 250 mg of a potassium salt of compound of structural formula:, and
(ii) administering to the subject a GLP1 agonist selected from exenatide, liraglutide, semaglutide, or dulaglutide,, wherein the potassium salt of step (i) is administered orally.